• Ankit Singh Department of Biotechnology, Madhav Institute of Technology and Science, Gwalior, M. P., India 474005.
  • Vinod Kumar Jatav Department of Biotechnology, Madhav Institute of Technology and Science, Gwalior, M. P., India 474005.
  • Sunita Sharma Department of Biotechnology, Madhav Institute of Technology and Science, Gwalior, M. P., India 474005.


Nil, Acetylcholinesterase, Rivastigmine`s, AutoDock 42, ADMET


Objective: Alzheimer's disease a progressive neurodegenerative disorder characterized by oxidative stress, amyloid β deposition and due to low level of neurotransmitter acetylcholine in the brain. the reduction of acetylcholine in the brain is due to enhance activity of acetyl cholinesterase enzyme. This study is done to find out the possible inhibiters of acetyl cholinesterase. In lieu of that, the present study focus on to find possible analogs of known drug Rivastigmine.

Methods: Protein for study is retrieved through protein databank (PDB ID - 1B41) and constrains was removed using Swiss-pdbviewer. Analogs for docking were chosen from zinc database and docking was performed using Autodock 4.2, after docking ADME analysis and toxicity were done against the possible inhibitors.

Results: Out of fifty analogs chosen for docking only nine analogs showed minimum binding energy and good RMS value, out of that analogs two with id ZINC00004413 and ZINC967938 shows good results so they were chosen for ADME analysis and toxicity prediction.

Conclusion: The possible analogs obtained after study can be further used for study and preparation of novel drug against Alzheimer's disease.


Download data is not yet available.


Akhtar MN, Lam KW, Abas F, Ahmad MS, Shah SAA, Atta-ur-Rahman M, et al. New class of acetylcholinesterase inhibitors from the stem bark of Knema laurina and their structural insights. Bioorg Med Chem Lett 2011;21:4097-103.

Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in europe: a collaborative study of population based cohorts. neurologic diseases in the elderly research group. Neurology 2000;54(11 Suppl 5):S10–5.

Evans DA, Funkenstein H, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO. JAMA 1989;262:2551.

Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:1379-147.

Kennedy DO, Dodd FL, Robertson BC, Okello EJ, Reay JL, Scholey AB, et al. Monoterpenoid extract of sage (Salvia lavandulaefolia) with cholinesterase inhibiting properties improves cognitive performance and mood in healthy adults. J Psychopharmacol 2010;doi: 10.11.77/0269881110385594.

Inestrosa NC, Alvare A, Garrido J. In Alzheimer's Disease: Biology, Diagnosis and Therapeutics 1997: John Wiley and Sons, London; 1997. p. 500-10.

Camps P, Formosa X, Galdeano C, Gómez T, Munoz Torrero D, Ramirez L, et al. Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates. Chem Biol Interact 2010;187:411-5.

Birks J. Rivastigmine for Alzheimer's disease. Cochrane Database System Rev 2000;4:CD001191.

Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (Rivastigmine tartrate), a new Acetylcholinestrase inhibitor in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psycho Pharmacol 1998;1:55–65.

Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog Brain Res 1993;98:431-8.

Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Prog Brain Res 1999;318:633-8.

Farlow MR. Update on rivastigmine. Neurologist 2003;9(5):230-4.

Romano T Kroemer. Structure-Based Drug Design, Docking and Scoring. Curr Protein Pept Sci 2007;8:312-28.

Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer an environment for comparative protein modeling. Electrophoresis 1997;18:2714-2723.

Laurie AT, Jackson RM. Q-site Finder: an energy-based method for the prediction of protein-ligand binding sites. Bioinformatics 2005;21:1908-16.

Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. Drug Bank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006;1(34):D668-72.

Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, et al. Drug Bank 4.0:shedding new light on drug metabolism. Nucleic Acids Res 2014;42(1):D1091-7.

Noel MO'Boyle, Michael B, Craig AJ, Chris M, Tim V, Geoffrey RH. Open babel: an open chemical toolbox. J Chemoinformaticas 2011;3:33.

Goodsell DS, Morris GM, Halliday RS, Huey R, Belew RK, Olson AJ. Automated docking using a lamarckian genetic algorithm and empirical binding free energy function. J Computational Chem 1998;19:1639-62.

Abhik Seal, Riju Aykkal, Mriganka Ghosh. Docking study of HIV-1 reverse transcriptase with phytochemicals. Bioinformation 2011;5(10):430-9.



How to Cite

Singh, A., V. K. Jatav, and S. Sharma. “VIRTUAL SCREENING AND ADMET ANALYSIS FOR IDENTIFICATION OF INHIBITORS AGAINST ACETYLCHOLINESTERASE ASSOCIATED WITH ALZHEIMER’S DISEASE”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 6, no. 10, Oct. 2014, pp. 155-9,



Original Article(s)